Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
21.443
Zitationen
19
Autoren
2005
Jahr
Abstract
BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS: A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematologic toxic effects in 7 percent of patients. CONCLUSIONS: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Einordnung (Deutsch)
Diese Studie untersucht addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.. Die Arbeit trägt den Originaltitel „Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma" und ist relevant für die aktuelle Gesundheits- und MedTech-Forschung. Die Ergebnisse können für Kliniker, Forscher und Fachleute im Gesundheitswesen von Bedeutung sein.
Diese Kurzfassung dient der thematischen Einordnung und ersetzt nicht den Originaltext.
Ähnliche Arbeiten
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.833 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.917 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.094 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.460 Zit.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 · 7.768 Zit.
Autoren
Institutionen
- University Hospital of Lausanne(CH)
- Princess Margaret Hospital(NZ)
- Erasmus MC(NL)
- University of Tübingen(DE)
- Western University(CA)
- University Medical Center Utrecht(NL)
- Hôpital Notre-Dame(CA)
- Medical University of Vienna(AT)
- University Hospital Regensburg(DE)
- University Hospital of Bern(CH)
- Queen's University(CA)
- European Organisation for Research and Treatment of Cancer(BE)
- University of Calgary(CA)
- Ontario Institute for Cancer Research(CA)